Partial
Mostly Unaligned
Patient Risk:
Moderate
Summary
Only weight gain and peripheral edema/dizziness-somnolence are supported by the provided label excerpts; multiple mechanistic, definitional, and risk-modifier statements (fluid retention vs fat gain, appetite/activity contributions, specific onset timing, and higher-risk subgroup statements) are not supported.
Category Scores
Accurate Statements
Weight gain is a known side effect of pregabalin.
5.8 Weight Gain: “LYRICA treatment may cause weight gain.”
Pregabalin can cause peripheral edema (swelling) in some patients.
5.7 Peripheral Edema: “LYRICA treatment may cause peripheral edema.”
Pregabalin can cause sedation or dizziness.
5.5 Dizziness and Somnolence: “LYRICA may cause dizziness and somnolence.”
Unsupported Statements
Lyrica (pregabalin) is an anticonvulsant/nerve-pain medicine.
Provided excerpts do not explicitly support the exact phrasing/label characterization “anticonvulsant/nerve-pain medicine” as a labeled indication; 12.1 supports antiseizure/anti-nociceptive effects in animals but not the requested categorical wording.
Pregabalin can cause fluid retention in some people.
Label excerpt 5.7 discusses peripheral edema but does not use or establish the term/concept “fluid retention.”
Pregabalin can change appetite and how active people feel, which together can raise body weight over time.
5.8 describes weight gain related to dose/duration but does not discuss appetite or activity changes as causes.
Peripheral edema is fluid retention rather than fat gain.
5.7 does not define peripheral edema as “fluid retention rather than fat gain.”
Changes in appetite and reduced energy/activity can contribute to longer-term weight increase, especially with continued use.
Not supported in provided excerpts; 5.8 does not attribute weight gain to appetite/energy/activity changes.
Pregabalin can increase appetite in some people.
No provided label excerpt mentions appetite increase.
Sedation or dizziness can reduce day-to-day activity and make it easier to gain weight even without major dietary changes.
5.5 supports dizziness/somnolence but does not link them to reduced activity or weight gain causality/mechanism.
Pregabalin does not typically cause rapid weight gain overnight.
5.8 does not address onset timing such as “overnight” or “rapid” weight gain.
Weight gain with pregabalin more often develops gradually.
5.8 supports dose/duration relationship but does not explicitly characterize “gradual” onset.
The risk of weight gain is higher in people with fluid-retention tendencies.
Provided excerpts do not mention “fluid-retention tendencies” as a risk modifier.
The risk of weight gain is higher in people who experience edema after starting or increasing the dose.
Provided excerpts do not state that weight gain risk is higher in those who develop edema after starting/increasing dose.
The risk of weight gain is higher in people with noticeable appetite increase or sedation that reduces activity.
Provided excerpts do not support appetite increase or sedation-related reduced activity as risk modifiers for weight gain.
Weight gain can occur at the same dose.
5.8 states weight gain is related to dose and duration but does not state within-person occurrence “at the same dose” or without dose change.
Weight gain can develop after starting therapy even if the dose does not increase.
Provided excerpts do not explicitly state weight gain can develop after initiation without dose increase.
Contradictions
Important Omissions
No FDA-excerpted quantitative counseling details from 5.8 (e.g., proportion of patients with ≥7% gain in up to 14 weeks, dose/duration relationship) were included despite making multiple risk/trajectory statements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported mechanistic and risk-stratification claims may mislead about etiology and who is at higher risk; supported core safety signals (weight gain, peripheral edema, dizziness/somnolence) are present.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Unaligned
Primary Issue
Multiple causal and specificity statements about mechanisms (appetite/activity), definitions (edema as fluid retention vs fat), and risk modifiers/onset timing are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to statements explicitly supported in the provided excerpts (e.g., that LYRICA may cause dizziness/somnolence, peripheral edema, and may cause weight gain related to dose/duration) and remove or generalize mechanistic/risk-factor/onset timing specifics that are not stated.